This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: January 24, 2014
Last updated: November 10, 2016
Last verified: November 2016

Introduction: As employees spent most part of their time at the worksite, it provides a venue to address multiple individual risk factors and promote health. The America Heart Association (AHA) defined cardiovascular health using as metrics smoking status, body mass index, physical activity, diet, total cholesterol, blood pressure and fasting blood glucose.

Objective: Evaluate Bayer employees' cardiovascular health according to the AHA definition and the acceptance to engage in lifestyle change programs.

Methods: By the time of the annual occupational safety periodic medical examination, employees will receive an email with information about the cardiovascular health screening, exams requisition (fasting blood glucose and total cholesterol) and a copy of the written informed consent. If the employee accepts to participate, after providing a written informed consent, he will be evaluated according to the AHA cardiovascular health metrics. Data will be collected at the occupational safety electronic health record. After medical evaluation, employees will receive a printed feedback with their cardiovascular health score and will be referred to indicated lifestyle change programs (healthy weight, smoking cessation, diabetes control, high blood pressure control, dyslipidemia control).

After 12 months we will evaluate the percentage of employees who accept to participate; prevalence of the cardiovascular risk factors and distribution according to the AHA classification in ideal, intermediate and poor; adherence to lifestyle change programs.

Condition Intervention
Occupational Health Behavioral: Examination and survey

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Descriptive Observational Study of Cardiovascular Health Risk Factors in Workers of Bayer S.A. Company in São Paulo

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Cardiovascular health metrics on a three-point scale (poor, intermediate, ideal) [ Time Frame: 1 day ]
    Metrics are defined by the American Heart Association (AHA) [Lloyd-Jones and cols, 2010]

Secondary Outcome Measures:
  • Number of participants who are suggested to participate in a lifestyle change program and show up for at least one session [ Time Frame: Up to 4 weeks after cardiovascular examination ]

Enrollment: 361
Study Start Date: August 2013
Study Completion Date: October 2016
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Bayer Sao Paulo employees
Workers from Bayer in site Socorro who participate in the trial
Behavioral: Examination and survey
Routine medical examination as required by law and follow-up for lifestyle change program


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Bayer's employees (São Paulo, Brazil)

Inclusion Criteria:

  • Employees with 20 years of age or more that daily work at Bayer's site in São Paulo
  • Provide written informed consent

Exclusion Criteria:

  • Employees that will no longer work for Bayer in 30 days
  • Employees that are retired from work during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02055651

Sao Paulo, Brazil
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT02055651     History of Changes
Other Study ID Numbers: 17312
NN1325BR ( Other Identifier: Company internal )
Study First Received: January 24, 2014
Last Updated: November 10, 2016

Keywords provided by Bayer:
Risk factors processed this record on August 23, 2017